Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2019.1 vs Standard of Care in r/r DLBCL (DALY 2-EU)
NCT04844866Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Aug 2021
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 14
01
Overview
A Phase 2 trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Miltenyi Biomedicine GmbH. Started Aug 2021; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04844866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844866.